Pulmovant
The Senior Manager, Pharmacovigilance supports ongoing safety surveillance and risk management for respiratory therapeutics, including the Phase 3 PHrontier study. This role oversees case processing, signal detection, and aggregate safety reporting while ensuring compliance with global pharmacovigilance regulations. The position serves as a key safety partner to clinical development, regulatory affairs, and medical teams to advance drug safety operations.
Pulmovant is a clinical-stage biopharmaceutical company singularly focused on developing innovative inhaled therapies for pulmonary diseases, including pulmonary hypertension. The company's lead candidate, mosliciguat, is a potentially first-in-class once-daily inhaled treatment with a differentiated soluble guanylate cyclase (sGC) activation mechanism. Pulmovant is advancing mosliciguat through clinical trials with the goal of transforming the treatment paradigm for patients with pulmonary diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Pulmovant.
Pulmovant didn’t post a salary, so this is our estimate from similar listings.
Pulmovant completes enrollment for PH-ILD treatment trial
1 month ago
Senior Director, Safety & Pharmacovigilance
larimartherapeutics.com
Senior Director, Patient Safety & Pharmacovigilance
Latigobio
Director, Drug Safety & Pharmacovigilance
Xencor
Director, Safety Scientist, Pharmacovigilance
MapLight Therapeutics
Director/Senior Director, Drug Safety & Pharmacovigilance
Faeth Therapeutics
Associate Director, Pharmacovigilance Scientist
Tango Therapeutics